Humacyte, Inc.
HUMAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHumacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions. The company carries a $180.9M market cap, placing it firmly in the micro-cap category. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Market Cap
$180.9M
Beta
2.52
P/E (TTM)
—
P/E (Fwd)
-2.79
EPS (TTM)
$-0.65
EPS (Fwd)
$-0.24
ROE
-409.5%
ROA
-51.5%
Cash
$48.5M
Total Debt
$66.5M
Free CF
-$64.8M
52W Change
-70.8%
Annual Financials
Cash vs Debt
Where HUMA stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, HUMA finished 28.28% below its 150-day moving average ($0.99) and 36.61% below its 200-day moving average ($1.12). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HUMA overbought or oversold?
At the July 15, 2026 close, HUMA's RSI(14) was 50.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $48.5M in cash, though total debt stands at $66.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$64.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -409.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Humacyte, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HUMA.